He is the founder and managing partner of City Hill Ventures, a boutique life sciences investment fund. He currently serves as the chairman and CEO of Ignyta, a City Hill portfolio company. He previously led San Diego-based Halozyme Therapeutics, beginning in 2003 when Halozyme was a privately held startup with five employees. Under his leadership, Halozyme became a public company, raised $300 million through financings and corporate partnerships, achieved two U.S. FDA approvals (one drug and one device), and built a deep pipeline of late-stage clinical drug candidates. He also was a management consultant with McKinsey & Co., an NIH postdoctoral fellow at Harvard University, and a general surgery resident at New York Hospital-Cornell. He holds B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard.